ConductScience.org, home

Paper38204331

Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease.

Ringdén O and 1 other. Stem Cells, 2024. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease. Papers, record 38204331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38204331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease.
PubMed
Journal
Stem Cells
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
1.55, provisional
iCite
Revised in PubMed
2025-07-18
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ringdén OOlle
2Sadeghi BBehnamhttps://orcid.org/0000-0002-8721-0400

Source PubMed

Download CSV of authors

Topics24

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Graft vs Host DiseaseMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
Mesenchymal Stem Cell TransplantationMajor topic
Mesenchymal Stem CellsMajor topic
Animals
Female
Humans
Mice
Middle Aged
Rabbits
Rats
Acute Disease
Decidua
Immunosuppressive Agents
Stromal Cells
Infant
Child, Preschool
Child
Adolescent
Young Adult
Adult
Aged
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
CAN 2018,419Swedish Cancer SocietyPubMed
111293Cancer Society in StockholmPubMed

Source PubMed

Download CSV of grants

References114

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136333233Immunomodulation by placenta-derived decidua stromal cells. Role of histocompatibility, accessory cells and freeze-thawing.Cytotherapy2023https://conductscience.org/library/papers/36333233PubMed
235853610Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.Transplant Cell Ther2022https://conductscience.org/library/papers/35853610PubMed
323307526Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease.Stem Cells2013https://conductscience.org/library/papers/23307526PubMed
431817480Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.Cells2019https://conductscience.org/library/papers/31817480PubMed
530697701Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.Cochrane Database Syst Rev2019https://conductscience.org/library/papers/30697701PubMed
618371435Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide.Cell Stem Cell2008https://conductscience.org/library/papers/18371435PubMed
75654088Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.Transplantation1968https://conductscience.org/library/papers/5654088PubMed
832044400Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children.Biol Blood Marrow Transplant2020https://conductscience.org/library/papers/32044400PubMed
935371003Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.Front Immunol2022https://conductscience.org/library/papers/35371003PubMed
1022966167Mesenchymal stem cells are injured by complement after their contact with serum.Blood2012https://conductscience.org/library/papers/22966167PubMed
1130711482Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines.Trends Mol Med2019https://conductscience.org/library/papers/30711482PubMed
1211772882Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart.Circulation2002https://conductscience.org/library/papers/11772882PubMed
1327299362Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ Licensing.Stem Cells2016https://conductscience.org/library/papers/27299362PubMed
1426765648Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis.Lancet Haematol2016https://conductscience.org/library/papers/26765648PubMed
1519282026Graft-versus-host disease.Lancet2009https://conductscience.org/library/papers/19282026PubMed
1632320566Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.N Engl J Med2020https://conductscience.org/library/papers/32320566PubMed
1725162829Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling.Stem Cells Dev2015https://conductscience.org/library/papers/25162829PubMed
1820130212Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression.J Immunol2010https://conductscience.org/library/papers/20130212PubMed
1931989101Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis.EClinicalMedicine2020https://conductscience.org/library/papers/31989101PubMed
2016338616National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.Biol Blood Marrow Transplant2005https://conductscience.org/library/papers/16338616PubMed

See all 114 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
41324806Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy.Mol Biol Rep2025https://conductscience.org/library/papers/41324806PubMed
40660274The rise of exosome-mediated mechanisms in MSC therapy.J Transl Med2025https://conductscience.org/library/papers/40660274PubMed
40515888Mesenchymal Stromal Cells and Graft-versus-Host Disease: Preclinical and Clinical Studies.Stem Cell Rev Rep2025https://conductscience.org/library/papers/40515888PubMed
39329708Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD.Cells2024https://conductscience.org/library/papers/39329708PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38204331

GET https://conductscience.org/api/papers/v1/38204331/references?page=2